From: Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study
Treatment completion | 3RHI daily | 3RPHII weekly | OtherIII | Total |
---|---|---|---|---|
Number of individuals | 399 | 306 | 21 | 726 |
Duration of treatment (days), median [IQR]* | 90 [73–156] | 77 [70–98] | – | – |
Treatment completion | ||||
 Completed according to physiciana | 357 (89.5) | 284 (92.8) | 17 (80.9) | 658 (90.6) |
 Missing information | 3 (0.8) | 4 (1.3) | – | 7 (1.0) |
 Incomplete treatment | 39 (10) | 18 (5.9) | 4 (19.0) | 61 (8.4) |
Reasons for incomplete treatment | ||||
 LTBI excluded | 4 (1.0) | – | – | 4 (0.6) |
 Diagnosed with TB disease | 1 (0.3) | – |  | 1 (0.1) |
 Patient choice | 4 (1.0) | 2 (0.7) | – | 6 (0.8) |
 Lost to follow-up | 1 (0.3) | 3 (1.0) | – | 4 (0.6) |
 Other or unknown | 3 (0.8) | 2 (0.7) |  | 5 (0.7) |
 Termination due to adverse effectsb | 26 (6.5) | 11 (3.4) | 4 (19.0) | 41 (5.6) |
  Hepatotoxicity (grade 1–2)c | 8 (2.0) | – | – | 8 (1.1) |
  Hepatotoxicity (grade 3–4)c | 5 (1.6) | 2 (0.7) | 1 (4.8) | 8 (1.1) |
  Gastrointestinal symptoms | 10 (2.5) | 8 (2.6) | 2 (9.5) | 20 (2.8) |
  Fatigue | 6 (1.5) | 8 (2.6) | 1 (4.8) | 15 (2.1) |
  Flu-like symptoms | 2 (0.5) | 4 (1.3) | 1 (4.8) | 7 (1.0) |
  Skin rash | 2 (0.5) | 1 (0.3) | 1 (4.8) | 4 (0.6) |
  Peripheral neuropathy | 1 (0.3) |  |  | 1 (0.1) |
  Joint pain | – | 2 (0.6) | – | 2 (0.3) |
  Other symptomsd | 2 (0.5) | 3 (1.0) | 2 (9.5) | 7 (1.0) |